Advances in understanding and managing rosacea: Part 2 - The central role, evaluation, and medical management of diffuse and persistent facial erythema of rosacea

Journal of Clinical and Aesthetic Dermatology

Volumn 5, Issue 3, 2012, Pages 26-36

  Del Rosso, James Q ^a,b,c  

^a VALLEY HOSPITAL MEDICAL CENTER   (United States)

^b TOURO UNIVERSITY NEVADA   (United States)

^c Las Vegas Skin & Cancer Clinics Ltd   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AZELAIC ACID; BRIMONIDINE; CALCINEURIN INHIBITOR; CLINDAMYCIN; DOXYCYCLINE; ISOTRETINOIN; MACROLIDE; METRONIDAZOLE; OXYMETAZOLINE; PIMECROLIMUS; RETINOID; TACROLIMUS; XYLOMETAZOLINE;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CLINICAL FEATURE; DERMATOLOGICAL PROCEDURE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; ERYTHEMATOTELANGIECTATIC ROSACEA; FACE ERYTHEMA; FOLLOW UP; HUMAN; OFF LABEL DRUG USE; PAPULOPUSTULAR ROSACEA; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHYMATOUS ROSACEA; REBOUND; REVIEW; ROSACEA; SIDE EFFECT; TACHYPHYLAXIS; TREATMENT OUTCOME;

EID: 84860352890     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (119)

1. Marks R. The enigma of rosacea. J Dermatol Treat. 2007;18:326-328. (Pubitemid 350223201)
2. Crawford GH, Pelle MT, James WD. Rosacea I: etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51:327-341. (Pubitemid 39178655)
3. Pelle MT, Crawford GH, James WD. Rosacea II: therapy. J Am Acad Dermatol. 2004;51:499-512.
4. Del Rosso JQ. Update on rosacea pathogenesis and correlation with medical therapeutic agents. Cutis. 2006;78:97-100. (Pubitemid 44433118)
5. Sapadin AN, Fleischmajer R. Tetracyclines: non-antibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54:258-265. (Pubitemid 43144395)
6. Bevins CL, Liu FT. Rosacea: skin innate immunity gone awry? Nat Med. 2007;13(8):904-906. (Pubitemid 47222032)
7. Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007;13(8):975-980. (Pubitemid 47222043)
8. Yamasaki K, Gallo RL. The molecular pathology of rosacea. J Dermatol Sci. 2009;55(2):77-81.
9. Fleischer AB. Inflammation in rosacea and acne: implications for patient care. J Drugs Dermatol. 2011;10:614-620.
10. Steinhoff M, Buddenkotte J, Aubert J, et al. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Invest Dermatol. 2011;15:2-11.
11. Meyer-Hoffert U, Schroder JM. Epidermal proteases in the pathogenesis of rosacea. J Invest Dermatol. 2011;15:16-23.
12. Gerber PA, Buhren BA, Steinhoff M, et al. Rosacea: the cytokine and chemokine network. J Invest Dermatol. 2011;15:40-47.
13. Schwab VD, Sulk M, Seeliger S, et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Invest Dermatol. 2011;15:53-62.
14. Rosina P, Zamperetti M, Giovannini A, et al. Video-capillaroscopic alterations in erythematotelangiectatic rosacea. J Am Acad Dermatol. 2006;54:100-104.
15. Jang YH, Sim JH, Kang HY, et al. Immunohistochemical expression of matrix metalloproteinases in the granulomatous rosacea compared with the non-granulomatous rosacea. J Eur Acad Dermatol Venereol. 2011;25:544-548.
16. Wilkin J, Dahl M, Detmar M, et al. Standardized classification system of rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2002;46:584-587.
17. Wilkin J, Dahl M, Detmar M, et al. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2004;50:907-912. (Pubitemid 38685771)
18. Yamasaki K, Gallo RL. Rosacea as a disease of cathelicidins and skin innate immunity. J Invest Dermatol. 2011;15:53-62.
19. De Y, Chen Q, Schmidt AP, et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL-1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med. 2000;192:1069-1074.
20. Koczulla R, von Degenfeld G, Kupatt C, et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest. 2003;111:1665-72. (Pubitemid 38057748)
21. Park HJ, Cho DH, Kim HJ, et al. Collagen synthesis is suppressed in dermal fibroblasts by the human antimicrobial peptide LL-37. J Invest Dermatol. 2009;129:843-50.
22. Korting HC, Schollmann C. Tetracycline actions relevant to rosacea treatment. Skin Pharmacol Physiol. 2009;22: 287-294.
23. Gomaa AH, Yaar M, Eyada MM, et al. Lymphangiogenesis and angiogenesis in non-phymatous rosacea. J Cutan Pathol. 2007;34:748-755
24. Guzman-Sanchez DA, Ishiuji Y, et al. Enhanced skin blood flow and sensitivity to noxious heat stimuli in papulopustular rosacea. J Am Acad Dermatol. 2007;57:800-805. (Pubitemid 47553073)
25. Huggenberger R, Detmar M. The cutaneous vascular system in chronic skin inflammation. J Invest Dermatol. 2011;15: 24-32.
26. Tjabringa GS, Aarbiou J, Ninaber DK, et al. The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor. J Immunol. 2003;171:6690-6696. (Pubitemid 37532101)
27. Tokumaru S, Sayama K, Skirakata Y, et al. Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37. J Immunol. 2005;175:4662-4668. (Pubitemid 41362007)
28. Detmar M, Brown LF, Claffey KP, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med. 1994;180: 1141-1146. (Pubitemid 24256627)
29. Bamford JTM. Rosacea: current thoughts on origin. Semin Cutan Med Surg. 2001;20:199-206. (Pubitemid 32927782)
30. Steinhoff M, Stander S, Seelinger S, et al. Modern aspects of cutaneous neurogenic inflammation. Arch Dermatol. 2003;139:479-488.
31. Cevikbas F, Steinhoff A, Homey B, et al. Neuroimmune interactions in allergic skin diseases. Curr Opin Allergy Clin Immunol. 2007;7:365-373. (Pubitemid 47415278)
32. Lazaridou E, Giannopoulou C, Fotiadou C, et al. The potential role of microorganisms in the development of rosacea. J Dtsch Dermatol Ges. 2011;9:21-25.
33. Yamasaki K, Kanada K, Macleod DT, et al. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J Invest Dermatol. 2011;131:688-697.
34. Dirschka T, Tronnier H, Folster-Holst R. Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis. Br J Dermatol. 2004;150:1136-1141. (Pubitemid 38932283)
35. Draelos ZD. Treating beyond the histology of rosacea. Cutis. 2004;74(suppl 3):28-31. (Pubitemid 39330115)
36. Torok HM. Rosacea skin care. Cutis. 2000;66(4 Suppl):14-16.
37. McAleer MA, Fitzpatrick P, Powell FC. Papulopustular rosacea: prevalence and relationship to photodamage. J Am Acad Dermatol. 2010;63:33-39.
38. Martin DB, Gaspari AA. Toll-like receptors. In: Gaspari AA, Tyring SK, eds. Clinical and Basic Immunology. London: Springer-Verlag; 2008:67-84.
39. Hansen C, Leitenberger JJ, Jacobe HT, et al. Photoimmunology. In: Gaspari AA, Tyring SK, Eds. Clinical and Basic Immunology. London: Springer-Verlag; 2008:147-155.
40. Chung J, Cho S, Kang S. Why does the skin age? Intrinsic aging, photoaging, and their pathophysiology. In: Rigel DS, Weiss RA, Lim HW, Dover JS, eds. Photoaging. New York: Marcel Dekker; 2004:1-13.
41. Neumann E, Frithz A. Capillaropathy and capillaroneogenesis in the pathogenesis of rosacea. Int J Dermatol. 1998;37: 263-266. (Pubitemid 28189686)
42. Lundwall A, Brattsand M. Kallikrein-related peptidases. Cell Mol Life. 2008;65:2019-2038.
43. Sotiropoulo G, Pampalakis G, Diamandis EP. Functional roles of human kallikrein-related peptidases. J Biol Chem. 2009;284:32989-32994.
44. Lefkove BA, Fried LE, Arbiser JL. Angiogenesis for the clinician. In: Gaspari AA, Tyring SK, Eds. Clinical and Basic Immunology. London: Springer-Verlag; 2008:157-168.
45. Oztas MO, Balk M, Ogus E, et al. The role of free radicals in the aetiopathogenesis of rosacea. Clin Exp Dermatol. 2003;28:188-192. (Pubitemid 36459629)
46. Tisma VS, Basta-Juzbasic A, Jaganjac M, et al. Oxidative stress and ferritin expression in the skin of rosacea patients. J Am Acad Dermatol. 2009;60:270276.
47. McAleer MA, Lacey N, Powell FC. The pathophysiology of rosacea. G Ital Dermatol Venereol. 2009;144:663-671.
48. Bielenberg DR, Bucana CD, Sanchez R, et al. Molecular regulation of UVB-induced cutaneous angiogenesis. J Invest Dermatol. 1998;111:864-872. (Pubitemid 28509331)
49. Karincaoglu Y, Bayram N, Aycan O, et al. The clinical importance of Demodex folliculorum presenting with nonspecific facial signs and symptoms. J Dermatol. 2004;31:618-626. (Pubitemid 39243784)
50. Forstinger C, Kittler H, Binder M. Treatment of rosacea-like demodicidosis with oral ivermectin and topical permethrin cream. J Am Acad Dermatol. 1999;41:775-777. (Pubitemid 29514037)
51. Larios G, Alevizos A, Perimeni D, et al. Rosacea-like demodicidosis. Lancet Infect Dis. 2008;8:804.
52. Segal R, Mimouni D, Feuerman H, et al. Dermoscopy as a diagnostic tool in demodicidosis. Int H Dermatol. 2010;49:1018-1023.
53. Bikowski JB, Del Rosso JQ. Demodex dermatitis: a retrospective analysis of clinical diagnosis and successful treatment with topical crotamiton. J Clin Aesthet Dermatol. 2009;2:20-25.
54. Bonamigo RR, Bakos L, Edelweiss M, et al. Could matrix metalloproteinase-9 be a link between Demodex folliculorum and rosacea? J Eur Dermatol Venereol. 2005;19:646-647. (Pubitemid 41742858)
55. Thibotout D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled randomized phase III studies. J Am Acad Dermatol. 2003;48:836-845. (Pubitemid 36706214)
56. Elewski B, Fleischer AB, Pariser DM et al. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea. Arch Dermatol. 2003;139:1444-50. (Pubitemid 37433134)
57. Del Rosso JQ, Baum EW. Comprehensive medical management of rosacea: an interim study report and literature review. J Clin Aesthetic Dermatol. 2008;1:20-25.
58. Subramanyan K. Role of mild cleansing in the management of patient skin. Dermatol Ther. 2004;17(4 suppl):26-34.
59. Elias PM. The skin barrier as an innate immune element. Semin Immunopath. 2007;29:3-14. (Pubitemid 47596384)
60. Quarterman MJ, Johnson DW, Abela DC, et al. Ocular rosacea: signs, symptoms, and tear studies before and after treatment with doxycycline. Arch Dermatol. 1997;133:49-54. (Pubitemid 27044305)
61. Odom RDahl M, Dover J, et al. Standard management options for rosacea, part 1: overview and broad spectrum of care. Cutis. 2009;84:43-47.
62. Bae YI, Yun SJ, Lee JB, et al. Clinical evaluation of 168 Korean patients with rosacea: the sun exposure correlates with the erythematotelangiectatic subtype. Ann Dermatol. 2009;21:243-249.
63. Del Rosso JQ. Medical treatment of rosacea with emphasis on topical therapies. Expert Opin Pharmacother. 2004;5:5-13. (Pubitemid 38072714)
64. McClellan KJ, Noble S. Topical metronidazole: a review of its uses in rosacea. Am J Clin Dermatol. 2000;1:191-199.
65. Frampton JE, Wagstaff AJ. Azelaic acid 15% gel in the treatment of papulopustular rosacea. Am J Clin Dermatol. 2004;5:57-64. (Pubitemid 38316544)
66. Liu RH, Smith MK, Basta SA, et al. Azelaic acid in the treatment of papulopustular rosacea: a systematic review of randomized controlled trials. Arch Dermatol. 2006;142: 1047-1052. (Pubitemid 44268483)
67. Del Rosso JQ, Baldwin H, Webster G. American Acne & Rosacea Society rosacea medical management guidelines. J Drugs Dermatol. 2008;7:531-533.
68. Odom RDahl M, Dover J, et al. Standard management options for rosacea, part 2: options according to rosacea subtype. Cutis. 2009;84:97-104.
69. Del Rosso JQ, Webster GW, Jackson M, et al. Two randomized phase II clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56:791-801.
70. Kennedy Carney C, Cantrell W, Elewski BE. Rosacea: a review of current topical, systemic and light based therapies. G Ital Dermatol Venereol. 2009;144:673-688.
71. Shanler SD, Ondo AL. Successful treatment of erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor antagonist, oxymetazoline. Arch Dermatol. 2007;143:1369-1371. (Pubitemid 350146279)
72. Kim JH, Oh YS, Ji JH, et al. Rosacea (erythemato-telangiectatic type) effectively improved by topical xylometazoline. J Dermatol. 2011;38:510-513.
73. Metrogel 1% Gel [package insert]. Fort Worth, Texas: Galderma Laboratories LP.
74. Finacea Gel [package insert]. Morristown, New Jersey: Bayer Dermatology Division (formerly Intendis); 2010.
75. Oracea Capsules [package insert]. ort Worth, Texas: Galderma Laboratories LP.
76. Del Rosso JQ. Anti-inflammatory dose doxycycline in the treatment of rosacea. J Drugs Dermatol. 2009;8:664-668.
77. Webster GF. An open-label, community-based, 12-week assessment of the effectiveness and safety of monotherapy with doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads). Cutis. 2010;86(5 Suppl):7-15.
78. Del Rosso JQ, Bhatia N. Azelaic acid gel 15% in the management of papulopustular rosacea: a status report on available efficacy data and clinical application. Cutis. 2011;88:67-72.
79. Gupta AK, Chaudhry MM. Critical review of the manner in which the efficacy of therapies for rosacea are evaluated. Int J Dermatol. 2003;42:909-916. (Pubitemid 37441462)
80. Fowler JF Jr. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. J Drugs Dermatol. 2007;6:641-645.
81. Del Rosso JQ, Schlessinger J, Werschler P. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. J Drugs Dermatol. 2008;7:573-576.
82. Del Rosso JQ, Bruce S, Jarratt M, et al. Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild-to-moderate papulopustular rosacea. J Drugs Dermatol. 2010;9:607-613.
83. Miyachi Y. Potential antioxidant mechanism of action for metronidazole: implications for rosacea management. Adv Ther. 2001;18:237-243. (Pubitemid 34117279)
84. Narayanan S, Hünerbein A, Getie M, et al. Scavenging properties of metronidazole on free oxygen radicals in a skin lipid model system. J Pharm Pharmacol. 2007;59:1125-30.
85. Akamatsu, H, Oguchi, M, Nishijima S, et al. The inhibition of free radical generation by human neutrophils through the synergistic effects of metronidazole with palmitoleic acid: a possible mechanism of action of metronidazole in rosacea and acne. Arch Dermatol.Res. 1990;282: 449-454. (Pubitemid 20350067)
86. Akamatsu, H, Komura J, Asada Y, et al. Inhibitory effect of azelaic acid on neutrophil functions: a possible cause for its efficacy in treating pathogenetically unrelated disease. Arch Dermatol Res. 1991;283:162-166.
87. Yamasaki K, Gallo RK et al. Effect of azelaic acid on cathelicidin and serine protease expression. Presented at: Fall Clinical Dermatology Conference; October 15-18 2009; Las Vegas, NV.
88. Webster G, Del Rosso JQ. Anti-inflammatory activity of tetracyclines. Dermatol Clin. 2007;25:122-135.
89. Golub LM, Lee HM, Ryan ME, et al. Tetracyclines inhibit connective tissue breakdown by multiple nonantimicrobial mecahanisms. Adv Derm Res. 1998;12:12-26.
90. Kanada KN, Nakatsuji T, Gallo RL. Doxycycline indirectly inhibits proteolytic activation of tryptic kallikrein-related peptidases and activation of cathelicidin. J Invest Dermatol. 2012 (accepted for publication). [Personal communication, Richard L. Gallo, MD; January 5, 2012].
91. James WD, Berger TG, Elston DM. Skin: basic structure and function. In: James WD, Berger TG, Elston DM, eds. Andrews' Diseases of the Skin Clinical Dermatology, 10th Edition. Phildelphia: Saunder Elsevier; 2006:12.
92. Rowell LB. Reflex control of the cutaneous vasculature. J Invest Dermatol. 1977;69:154-166. (Pubitemid 8130723)
93. Johnson JM, Kellogg DL. Local thermal control of human cutaneous circulation. J Appl Physiol. 2010;109:1229-1238.
94. Piascik MT, Perez DM. Alpha1-adrenergic receptors: new insights and directions. J Pharmacol Exp Ther. 2001;298: 403-410. (Pubitemid 32673390)
95. Civantos Calzada B, Aleixandre de Artinano A. Alpha-adrenoreceptor subtypes. Pharmacol Res. 2001;44:195-208.
96. Guimaraes S, Moura D. Vascular adrenoreceptors: an update. Pharmacol Rev. 2001;53:319-356.
97. Leech CJ, Faber JE. Different alpha-adrenoreceptor subtypes mediate constriction of arterioles and venules. Am J Physiol. 1996;270 (2, pt 2):H710-H722
98. Hieble JP. Subclassification and nomenclature of alpha- and beta-adrenoreceptors. Curr Top Med Chem. 2007;7:129-134.
99. Kim MB, Kim GW, Park HJ, et al. Pimecrolimus 1% cream for the treatment of rosacea. J Dermatol. 2011;38:1135-1139.
100. Weissenbacher S, Merkl J, Hildebrandt B, et al. Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial. Br J Dermatol. 2007;156: 728-32. (Pubitemid 46452339)
101. Koca R, Altinyazar HC, Ankarali H, et al. A comparison of metronidazole 1% cream and pimecrolimus 1% cream in the treatment of patients with papulopustular rosacea: a randomized open-label clinical trial. Clin Exp Dermatol. 2010;35:251-256.
102. Garg G, Thami GP. Clinical efficacy of tacrolimus in rosacea. J Eur Acad Dermatol Venereol. 2009;23:239-240.
103. Ertl GA, Levine N, Kligman AM. A comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea. Arch Dermatol. 1994;130:319-324. (Pubitemid 24107870)
104. Park H, Del Rosso JQ. Use of oral isotretinoin in the management of rosacea. J Clin Aesthet Dermatol. 2011;4: 54-61.
105. Rebora A. The management of rosacea. Am J Clin Dermatol. 2002;3:489-496. (Pubitemid 35007066)
106. Buechner SA. Rosacea: an update. Dermatology. 2005;210:100-08. (Pubitemid 40463198)
107. Gupta AK, Chaudhry MM. Rosacea and its management: an overview. J Eur Acad Dermatol Venereol. 2005;19:273-85. (Pubitemid 40691703)
108. Ramey JT, Bailen E, Lockey RF. Rhinitis medicamentosa. J Investig Allerg Clin Immunol. 2006;16:148-155.
109. Graf P. Long term use of oxy- and xylometazoline nasal sprays induces rebound swelling, tolerance, and nasal hyper-reactivity. Rhinology. 1996;34:9-13. (Pubitemid 26155374)
110. Alphagan-P Opthalmic Solution 0.1% and 0.15% [package insert]. Irvine, California: Allergan Inc.; 2011.
111. Fowler J, Jarratt M, Moore A, et al. Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment of moderate to severe facial erythema of rosacea: results of two multicenter, randomized and vehicle-controlled studies. Br J Dermatol. 2011 Nov 2. doi: 10.1111/j.1365-2133.2011. 10716.x. [Epub ahead of print].
112. Rahman MQ, Ramaesh K, Montgomery DNI. Brimonidine for glaucoma. Expert Opin Drug Saf. 2010;9:483-491.
113. Mark K, Sparacio RM, Voigt A, et al. Objective and quantitative improvement of rosacea-associated erythema after intense pulsed light treatment. Dermatol Surg. 2003;29:600-604. (Pubitemid 36702444)
114. Papageorgiou P, Clayton W, Norwood S, et al. Treatment of rosacea with intense pulsed light: significant treatment and long-lasting results. Br J Dermatol. 2008;159:628-632.
115. Neuhaus IM, Zane LT, Tope WD, et al. Comparative efficacy of nonpurpuragenic pulsed dye laser and intense pulsed light for erythematotelangiectatic rosacea. Dermatol Surg. 2009;35:920-928.
116. Clark SM, Lanigan SW, Marks R. Laser treatment of erythema and telangiectasia associated with rosacea. Lasers Med Sci. 2002;17:26-33. (Pubitemid 34145977)
117. Tan SR, Tope WD. Pulsed dye laser treatment of rosacea improves erythema, symptomatology, and quality of life. J Am Acad Dermatol. 2004;51:592-99. (Pubitemid 39278080)
118. Menezes N, Moreira A, Mota G, et al. Quality of life of rosacea: pulsed dye laser impact. J Cosmet Laser Ther. 2009;11:139-41.
119. Berg M, Edstrom DW. Flashlamp pulsed dye laser (FPDL) did not cure papulopustular rosacea. Lasers in Surg Med. 2004;34:266-268. (Pubitemid 38420429)